Contribute to Leiomyosarcoma Research
Click here to make an online donation with PayPal.
Donations by Mail
Click on the link below to make a donation by mail:
Invest in Research Breakthroughs To Advance Treatment:
Thank you for your gracious generosity and support!
NLMSF FUNDING SUPPORT FOR RESEARCH PROJECTS – Through “investing” in LMS Research, patients, families, friends came together to support /contribute to the Foundation ’s funding of important LMS research projects. All donations are investment “gifts” directed to LMS research – lighting the way to the discovery that can turn into clinical care treatment options . . . “gifts” that keep on giving!
YOUR DOLLARS IN ACTION:
- The Foundation supports the new research initiative for the P53 – the study of potentially targetable mutations – p53, with 10 additional elements that can be applied to LMS. The role of macrophages in tumor microenvironment for LMS – Anti-PD1 investigational research, comparing macrophages in LMS vs breast and colon cancer is beginning. Development of new antibody vs macrophage in combination with anti-PD-1 antibody is being investigated (Pembrolizumab and Optivo); validation of LMS cell lines and PDX models and SARC trial patients to search for targeted tumor signatures; identification of such tumor search signatures will benefit P13/mTOR, p53, LGF1R, ER therapies.
- The Specialized Program of Research Excellence (SPORE), a Sarcoma Alliance Through Research and Collaboration research project for new biologically-rational clinical trials in sarcoma, that hold promise for cross over progress in a variety of sarcoma subtypes, including LMS.
- Development of a non-invasive diagnostic assay for highly accurate pre-operative distinction between uterine leiomyomas and leiomyosarcomas. The detection of circulating tumor
DNA, reported in several cancers, but only a few in sarcomas and no large-scale study to detect ctDNA for LMS patients –inspired further study for sarcomas and brought a proof of principle study to include LMS patients to determine the feasibility of ctDNA analysis. Such an analysis would enable clinicians to identify patients who could safely undergo laparoscopic procedures using power morcellators. A “liquid biopsy” test based on the analysis of tumor-associated genetic aberrations in circulating tumor DNA (ctDNA) in plasma may be of great use such situations.
WHAT AN AMAZING IMPACT YOUR “INVESTMENT” DONATIONS ARE MAKING!